Lorus Therapeutics Signs Research and License Option Agreement with Elanco

Lorus Therapeutics Signs Research and License Option Agreement with Elanco 
Provides for Development and Commercialization of Selected Compounds 
TORONTO, ONTARIO -- (Marketwired) -- 04/17/13 -- Lorus Therapeutics
Inc. (TSX:LOR) ("Lorus"), a biopharmaceutical company specializing in
the discovery, research and development of pharmaceutical products
announced today that it has entered into a research and license
option agreement with Elanco, the animal health division of Eli Lilly
and Company, to investigate some of Lorus' compounds for veterinary
medicine. According to the agreement, Elanco will fund the research
program and has been granted an exclusive option to license the
worldwide rights for selected compounds for veterinary use; the terms
of which will be negotiated when the option is exercised by Elanco.
Lorus retains the rights to develop and commercialize these compounds
for human use. No further details of the deal were disclosed. 
"We are excited about this partnership with Elanco, a global leader
in veterinary medicine, and look forward to advancing these compounds
in veterinary medicine," said Dr. Aiping Young, President and CEO of
Lorus. "The support of Elanco enables us to accelerate the
development of this promising program with the ultimate goal of
bringing a drug from this program to the veterinary market in the
shortest possible timeframe."  
About Lorus  
Lorus is a biopharmaceutical company focused on the discovery,
research and development of novel therapeutics in cancer. The Company
also has expertise in antimicrobial drug discovery. Lorus' goal is to
capitalize on its research, preclinical, clinical and regulatory
expertise by developing new drug candidates that can be used, either
alone, or in combination with other drugs, to successfully manage
cancer. Lorus Therapeutics Inc. is listed on the Toronto Stock
Exchange under the symbol LOR. More information is available at
www.lorusthera.com. 
Forward-Looking Statements  
This press release may contain forward-looking statements within the
meaning of Canadian and U.S. securities laws. Such statements
include, but are not limited to, statements relating to: our ability
to fund future research, our research program plans, our ability to
continue as a going concern, our ability to maintain partnerships on
an ongoing basis, the potential of LOR-468 for treatment in humans or
animals, our ability to accelerate development of LOR-468, the
probability that LOR-468 will ever be commercialized or that it will
constitute a new or improved treatment, the current or future market
size of the pet industry, veterinary care and oncology markets and
anticipated growth, the amount pet owners are willing to spend on
veterinary care, the Company's plans, objectives, expectations and
intentions and other statements including words such as "continue",
"believe", "plan", "expect", "intend", "will", "should", "may", and
other similar expressions. Such statements reflect our current views
with respect to future events and are subject to risks and
uncertainties and are necessarily based upon a number of estimates
and assumptions that, while considered reasonable by us are
inherently subject to significant business, economic, competitive,
political and social uncertainties and contingencies. Many factors
could cause our actual results, performance or achievements to be
materially different from any future results, performance, or
achievements that may be expressed or implied by such forward-looking
statements, including, among others: our ability to continue as a
going concern, our ability to obtain the capital required for
research and operations, the inherent risks in early stage drug
development including demonstrating efficacy, development time/cost
and the regulatory approval process; the progress of our clinical
trials; our ability to find and enter into agreements with potential
partners; our ability to attract and retain key personnel; changing
market conditions; and other risks detailed from time-to-time in our
ongoing quarterly filings, annual information forms, annual reports
and annual filings with Canadian securities regulators and the United
States Securities and Exchange Commission.  
Should one or more of these risks or uncertainties materialize, or
should the assumptions set out in the section entitled "Risk Factors"
in our Annual Information Form underlying those forward-looking
statements prove incorrect, actual results may vary materially from
those described herein. These forward-looking statements are made as
of the date of this press release and we do not intend, and do not
assume any obligation, to update these forward-looking statements,
except as required by law. We cannot assure you that such statements
will prove to be accurate as actual results and future events could
differ materially from those anticipated in such statements.
Investors are cautioned that forward-looking statements are not
guarantees of future performance and accordingly investors are
cautioned not to put undue reliance on forward-looking statements due
to the inherent uncertainty therein.  
Lorus Therapeutics Inc.'s recent press releases are available through
the Company's website at www.lorusthera.com. For Lorus' regulatory
filings on SEDAR, please go to www.Sedar.com. 
Contacts:
Lorus Therapeutics Inc.
Grace Tse
416-798-1200 ext. 380
ir@lorusthera.com
www.lorusthera.com 
The Trout Group
Lee M. Stern
646-378-2922
 
 
Press spacebar to pause and continue. Press esc to stop.